| Not Yet Recruiting | Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. NCT07439172 | The Cooper Health System | Phase 2 |
| Recruiting | Tuvusertib in Astrocytoma With ATRX Mutation NCT07417761 | Grupo Español de Investigación en Neurooncología | Phase 2 |
| Recruiting | FearLess in NeuroOncology NCT06989086 | Virginia Commonwealth University | N/A |
| Active Not Recruiting | A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent M NCT06614855 | James Markert, MD | Phase 1 |
| Recruiting | Study of Olutasidenib and Temozolomide in HGG NCT06161974 | Rigel Pharmaceuticals | Phase 2 |
| Recruiting | Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients with Brain Lesions. NCT06797661 | Erasme University Hospital | N/A |
| Recruiting | Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma NCT06344130 | National Cancer Institute (NCI) | Phase 1 |
| Completed | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial NCT06439420 | Virginia Commonwealth University | Phase 2 |
| Suspended | Investigational Imaging Technique During Brain Surgery NCT05513859 | Emory University | N/A |
| Unknown | Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas NCT06241391 | All India Institute of Medical Sciences, Bhubaneswar | N/A |
| Recruiting | Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma NCT06108206 | Columbia University | N/A |
| Recruiting | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma NCT05879367 | Orbus Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma NCT05561374 | Oblato, Inc. | Phase 1 |
| Active Not Recruiting | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma NCT05484622 | Institut de Recherches Internationales Servier | Phase 1 |
| Recruiting | Venous Thromboembolism Prevention in Outpatients With Glioma NCT05683808 | University of Vermont Medical Center | Phase 2 |
| Not Yet Recruiting | Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma NCT05532969 | Henan Provincial People's Hospital | — |
| Recruiting | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. NCT05686798 | Henry Ford Health System | Phase 1 |
| Unknown | Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning NCT05624736 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Recruiting | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma NCT05345002 | Stephen Bagley, MD, MSCE | Phase 2 |
| Active Not Recruiting | Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma NCT05236036 | Northwestern University | Phase 1 |
| Withdrawn | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants NCT03649464 | Oblato, Inc. | Phase 1 / Phase 2 |
| Completed | Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas NCT05393258 | Washington University School of Medicine | N/A |
| Unknown | Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models NCT04970615 | Sümeyye Sezer | — |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Completed | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S NCT04430842 | Quadriga Biosciences, Inc. | Phase 1 |
| Recruiting | Implantable Microdevice In Primary Brain Tumors NCT04135807 | Oliver Jonas | EARLY_Phase 1 |
| Terminated | CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic A NCT04047303 | Celgene | Phase 1 |
| Active Not Recruiting | Pediatric Long-Term Follow-up and Rollover Study NCT03975829 | Novartis Pharmaceuticals | Phase 4 |
| Recruiting | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Social Determinants of Health in Glioblastoma Population NCT03900689 | Wake Forest University Health Sciences | — |
| Terminated | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases NCT03796273 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Completed | Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With Hi NCT03538587 | National Cancer Institute (NCI) | N/A |
| Active Not Recruiting | Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With NCT03739372 | University of California, San Francisco | N/A |
| Completed | Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma NCT06620926 | asmaa salama ibrahim | — |
| Recruiting | Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology NCT04648462 | Maastricht Radiation Oncology | — |
| Completed | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 NCT02684058 | Novartis Pharmaceuticals | Phase 2 |
| Active Not Recruiting | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 NCT03152318 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma NCT03032484 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Withdrawn | Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas NCT02976441 | Washington University School of Medicine | EARLY_Phase 1 |
| Terminated | Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotira NCT02942264 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | First in Patient Study for PF-06840003 in Malignant Gliomas NCT02764151 | Pfizer | Phase 1 |
| Unknown | Astrocytoma / Desmoplastic Gamliogliomes (DIA / DIG) - Study of the French Cohort of the Last 20 Years : Clini NCT03115164 | Centre Hospitalier Universitaire, Amiens | — |
| Completed | Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response Durin NCT02747407 | Wake Forest University Health Sciences | — |
| Completed | Radiomics for Prediction of Survival in GBM NCT02666066 | Maastricht Radiation Oncology | — |
| Completed | Nivolumab With DC Vaccines for Recurrent Brain Tumors NCT02529072 | Gary Archer Ph.D. | Phase 1 |
| Terminated | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance De NCT02372409 | Washington University School of Medicine | Phase 2 |
| Unknown | A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas NCT02209428 | Huashan Hospital | Phase 2 |
| Completed | Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma NCT02010606 | Cedars-Sinai Medical Center | Phase 1 |
| Terminated | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas NCT01849952 | Dartmouth-Hitchcock Medical Center | — |
| Terminated | Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas NCT01502605 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Neural Basis of Language Processing NCT02903784 | University Hospital, Montpellier | N/A |
| Recruiting | Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma NCT01649830 | Sun Yat-sen University | Phase 3 |
| Unknown | Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic NCT01579253 | Ludwig-Maximilians - University of Munich | — |
| Terminated | A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors NCT01351519 | MultiCare Health System Research Institute | Phase 2 |
| Completed | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors NCT01331135 | Emory University | Phase 1 |
| Completed | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminar NCT01125800 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 NCT04327011 | Tocagen Inc. | Phase 1 |
| Completed | Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation NCT01288235 | Massachusetts General Hospital | Phase 2 |
| Withdrawn | A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas NCT01117155 | National Cancer Institute (NCI) | — |
| Completed | A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With NCT00994071 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma NCT01044966 | Medical University of South Carolina | Phase 1 / Phase 2 |
| Completed | Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas NCT00782626 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas NCT00921167 | Clinical Research Center for Solid Tumor, Korea | Phase 2 |
| Completed | HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas NCT00874861 | Ian F. Pollack, M.D. | EARLY_Phase 1 |
| Completed | Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adult NCT00795457 | Ian F. Pollack, M.D. | EARLY_Phase 1 |
| Unknown | A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma NCT00683761 | TransMolecular | Phase 1 / Phase 2 |
| Unknown | FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma NCT01089244 | Ludwig-Maximilians - University of Munich | — |
| Completed | Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2) NCT00723827 | Merck Sharp & Dohme LLC | — |
| Unknown | Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma NCT00591058 | TransMolecular | Phase 1 |
| Completed | Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP) NCT00624728 | University Hospital, Bordeaux | Phase 1 / Phase 2 |
| Terminated | A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplast NCT00389090 | Keryx / AOI Pharmaceuticals, Inc. | Phase 2 |
| Completed | Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062) NCT00705198 | Merck Sharp & Dohme LLC | — |
| Completed | Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma NCT00575887 | Marmara University | Phase 2 |
| Completed | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma NCT00392171 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodend NCT00360828 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma NCT00335075 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Pati NCT00154375 | Novartis Pharmaceuticals | Phase 3 |
| Completed | SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patient NCT00783393 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Genetic Analysis of Brain Tumors NCT00031538 | National Cancer Institute (NCI) | — |
| Completed | Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer NCT00028158 | MediGene | Phase 1 / Phase 2 |
| Completed | Prolonged Daily Temozolomide for Low-Grade Glioma NCT00165360 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Natural History of Patients With Brain and Spinal Cord Tumors NCT00009035 | National Cancer Institute (NCI) | — |
| Completed | Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor NCT00001148 | National Institute of Neurological Disorders and Stroke (NINDS) | — |
| Completed | Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors NCT00179803 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 2 |
| Completed | Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma NCT03722355 | Radiation Therapy Oncology Group | Phase 3 |
| Completed | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas NCT00080054 | Pharmacyclics LLC. | Phase 1 |